32 related articles for article (PubMed ID: 18714599)
1. Cost burden of chemotherapy for Indonesian healthcare insurance and social security/Jaminan Kesehatan Nasional (JKN) patients with non-Hodgkin lymphoma.
Yulistiani Y; Abdissalam E; Rahem A; Hamidi NF; Utomo FN
J Oncol Pharm Pract; 2024 Jun; ():10781552241261250. PubMed ID: 38860280
[TBL] [Abstract][Full Text] [Related]
2. miRNA signature associated with R-CHOP refractoriness in patients diagnosed with diffuse large B cell lymphoma.
Fajardo-Ramirez OR; Villela L; Campa-Carranza JN; Perez-Maya AA; Borrego-Soto G; Wah-Suarez MI; Rodríguez-Sánchez IP; Zapata-Morin PA; Ortiz-Lopez R; Treviño VM; Garcia-Magariño M; Marino-Martinez IA
Noncoding RNA Res; 2020 Dec; 5(4):185-190. PubMed ID: 33134613
[TBL] [Abstract][Full Text] [Related]
3. Non-Hodgkin's Lymphoma Presenting as a Huge Ocular Adnexal and Forehead Mass.
Omoti AE; Omoti CE; Ogbeide OU
J Ophthalmic Vis Res; 2011 Jan; 6(1):47-50. PubMed ID: 22454706
[TBL] [Abstract][Full Text] [Related]
4. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
Vega MI; Huerta-Yepez S; Martinez-Paniagua M; Martinez-Miguel B; Hernandez-Pando R; González-Bonilla CR; Chinn P; Hanna N; Hariharan K; Jazirehi AR; Bonavida B
Clin Cancer Res; 2009 Nov; 15(21):6582-94. PubMed ID: 19861448
[TBL] [Abstract][Full Text] [Related]
5. Use of rituximab in combination with conventional chemotherapy for the treatment of non-Hodgkin's lymphoma of the head and neck.
Manolopoulos L; Gomatos IP; Leandros E; Alevizos L; Georgiou N; Giotakis J; Ferekidis E
In Vivo; 2009; 23(3):475-8. PubMed ID: 19454517
[TBL] [Abstract][Full Text] [Related]
6. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
Milani C; Castillo J
Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
[TBL] [Abstract][Full Text] [Related]
7. Emerging treatments for indolent lymphoma.
Cheson BD; Gregory SA; Marcus R
Clin Adv Hematol Oncol; 2007 May; 5(5 Suppl 8):1-9; quiz 11-2. PubMed ID: 17637594
[TBL] [Abstract][Full Text] [Related]
8. [Current therapeutic advances in the treatment of non-Hodgkin lymphoma].
Hernández-Rivera G; Aguayo-González A; Cano-Castellanos R; Loarca-Piña LM
Gac Med Mex; 2008; 144(3):275-7. PubMed ID: 18714599
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
10. Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approach.
Vose J
Clin Adv Hematol Oncol; 2005 Dec; 3(12):923-32. PubMed ID: 16555434
[TBL] [Abstract][Full Text] [Related]
11. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
Zhou X; Hu W; Qin X
Oncologist; 2008 Sep; 13(9):954-66. PubMed ID: 18779537
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
